Bicycle Therapeutics plc (NASDAQ:BCYC) Director Bros. Advisors Lp Baker Acquires 985,397 Shares

Bicycle Therapeutics plc (NASDAQ:BCYC) Director Bros. Advisors Lp Baker bought 985,397 shares of Bicycle Therapeutics stock in a transaction dated Friday, December 13th. The stock was acquired at an average price of $13.76 per share, with a total value of $13,559,062.72. Following the acquisition, the director now directly owns 9,537,643 shares of the company’s stock, valued at approximately $131,237,967.68. This represents a 11.52 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Monday, December 16th, Bros. Advisors Lp Baker purchased 500,000 shares of Bicycle Therapeutics stock. The shares were acquired at an average cost of $15.34 per share, for a total transaction of $7,670,000.00.

Bicycle Therapeutics Trading Up 0.1 %

BCYC stock opened at $15.14 on Wednesday. The firm has a market cap of $1.05 billion, a PE ratio of -4.60 and a beta of 0.86. Bicycle Therapeutics plc has a 1 year low of $12.17 and a 1 year high of $28.67. The company has a fifty day simple moving average of $22.62 and a 200 day simple moving average of $22.71.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The company had revenue of $2.68 million for the quarter, compared to analyst estimates of $6.82 million. During the same period last year, the company earned ($1.26) earnings per share. The business’s revenue was down 50.0% compared to the same quarter last year. As a group, analysts forecast that Bicycle Therapeutics plc will post -3.05 EPS for the current fiscal year.

Hedge Funds Weigh In On Bicycle Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BCYC. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in shares of Bicycle Therapeutics by 0.6% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 888,081 shares of the company’s stock worth $17,975,000 after buying an additional 4,976 shares during the last quarter. Pinnacle Associates Ltd. lifted its position in Bicycle Therapeutics by 202.2% during the 2nd quarter. Pinnacle Associates Ltd. now owns 242,001 shares of the company’s stock worth $4,898,000 after acquiring an additional 161,911 shares during the last quarter. Natixis Advisors LLC bought a new stake in Bicycle Therapeutics during the second quarter valued at about $261,000. TD Asset Management Inc increased its stake in shares of Bicycle Therapeutics by 76.7% in the second quarter. TD Asset Management Inc now owns 97,186 shares of the company’s stock worth $1,967,000 after purchasing an additional 42,200 shares during the period. Finally, Renaissance Technologies LLC lifted its position in shares of Bicycle Therapeutics by 97.2% during the 2nd quarter. Renaissance Technologies LLC now owns 326,800 shares of the company’s stock worth $6,614,000 after purchasing an additional 161,100 shares during the last quarter. Institutional investors and hedge funds own 86.15% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. HC Wainwright dropped their target price on Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating on the stock in a report on Monday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicycle Therapeutics in a research note on Monday, September 9th. Royal Bank of Canada reissued an “outperform” rating and set a $35.00 target price on shares of Bicycle Therapeutics in a research note on Friday, November 1st. JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 price target on shares of Bicycle Therapeutics in a research note on Monday, September 16th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $38.00 price objective on shares of Bicycle Therapeutics in a report on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $36.00.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.